Latest News and Press Releases

Continued positive development of IdeS in clinical studies Second quarter in brief Business highlights ›› US Food and Drug Administration (FDA) cleared Hansa Medical’s IND application for a study...

Fortsatt positiv utveckling av IdeS Andra kvartalet i korthet Verksamheten i sammandrag ›› FDA gav Hansa Medical klartecken att påbörja kliniska studier med IdeS inom njurtransplantation ›› Alla...

Hansa Medical AB (publ) har förvärvat Immago Biosystems Ltd, en avknoppning från University of Oxford, med inriktning på förstärkning av antikroppsbaserade cancerbehandlingar med hjälp av...

Hansa Medical AB (publ) today announced the acquisition of UK based Immago Biosystems Ltd, a University of Oxford-spinout focused on the enhancement of antibody based cancer therapies using...

Hansa Medical AB (publ) today announced that the company sponsored pivotal multicenter study in the US with IdeS in refractory highly sensitized patients is open for recruitment. The single arm Phase...

Hansa Medical AB (publ) meddelade idag att rekrytering av patienter till en registreringsgrundande amerikansk multicenterstudie med bolagets läkemedelskandidat IdeS i behandlingsresistenta...

Hansa Medical AB (publ) today announced that additional data from the ongoing US Phase II study with IdeS in kidney transplantation was presented at the 2016 American Transplant Congress (ATC) in...

Hansa Medical AB (publ) meddelade idag att ytterligare data från den pågående amerikanska fas II-studien med IdeS i njurtransplantation presenterades vid 2016 American Transplant Congress (ATC) i...

Dr. Tomas Lorant, principal investigator, will present data from the ongoing Swedish Phase II study with IdeS in sensitized kidney transplant patients at the 26thInternational Congress of the...

Dr. Tomas Lorant, ansvarig prövare, kommer att presentera data från den pågående svenska fas II-studien med IdeS i sensitiserade njurtransplantationspatienter vid The 26th International Congress of...